Bristol-Myers Squibb (NYSE:BMY) Raised to “Outperform” at Daiwa Capital Markets
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was upgraded by investment analysts at Daiwa Capital Markets from a “neutral” rating to an “outperform” rating in a research note issued on Wednesday, Marketbeat reports. Several other equities analysts also recently weighed in on BMY. UBS Group increased their price target on shares of Bristol-Myers Squibb from […]
More Stories
Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research note issued...
Tesla (NASDAQ:TSLA) Stock Price Expected to Rise, Royal Bank of Canada Analyst Says
Tesla (NASDAQ:TSLA – Get Free Report) had its price target upped by analysts at Royal Bank of Canada from $249.00...
HIVE Digital Technologies (NASDAQ:HIVE) Stock Price Expected to Rise, Northland Securities Analyst Says
HIVE Digital Technologies (NASDAQ:HIVE – Free Report) had its price target boosted by Northland Securities from $5.50 to $7.00 in...
Bristol-Myers Squibb (NYSE:BMY) Price Target Raised to $60.00
Bristol-Myers Squibb (NYSE:BMY – Free Report) had its target price increased by Citigroup from $55.00 to $60.00 in a research...
Hims & Hers Health (NYSE:HIMS) Lowered to “Underperform” Rating by Bank of America
Bank of America downgraded shares of Hims & Hers Health (NYSE:HIMS – Free Report) from a buy rating to an...
Morgan Stanley Forecasts Strong Price Appreciation for Smurfit Westrock (NYSE:SW) Stock
Smurfit Westrock (NYSE:SW – Free Report) had its price objective lifted by Morgan Stanley from $60.00 to $64.00 in a...